Download
journal.pone.0283658.pdf 698,41KB
WeightNameValue
1000 Titel
  • Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
1000 Autor/in
  1. Li, Jiaqi |
  2. Nakagawa, Takeshi |
  3. Kojima, Masayo |
  4. Nishikimi, Akihiko |
  5. Tokuda, Haruhiko |
  6. Nishimura, Kunihiro |
  7. Umezawa, Jun |
  8. Tanaka, Shiori |
  9. Inoue, Manami |
  10. Ohmagari, Norio |
  11. Yamaguchi, Koushi |
  12. Takeda, Kazuyoshi |
  13. Yamamoto, Shohei |
  14. Konishi, Maki |
  15. Miyo, Kengo |
  16. Mizoue, Tetsuya |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-04-06
1000 Erschienen in
1000 Quellenangabe
  • 18(4):e0283658
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0283658 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079051/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Patients with underlying medical conditions are at high risk of developing serious symptoms of the coronavirus disease 2019 than healthy individuals; therefore, it is necessary to evaluate the immune response to vaccination among them to formulate precision and personalized vaccination strategies. However, inconsistent evidence exists regarding whether patients with underlying medical conditions have lower anti-SARS-CoV-2 spike IgG antibody titers. We performed a cross-sectional study enrolling 2762 healthcare workers who received second doses of BNT162b2 vaccination from three medical and research institutes between June and July, 2021. Medical conditions were surveyed by a questionnaire, and spike IgG antibody titers were measured with chemiluminescent enzyme immunoassay using serum collected on the median of 62 days after the second vaccination. Multilevel linear regression model was used to estimate geometric mean and ratio of mean (95% confidence interval, CI) for the presence and absence of medical conditions and treatments. Among all participants (median age, 40 years [interquartile range, 30–50]; male proportion, 29.4%), the prevalence of hypertension, diabetes, chronic lung disease, cardiovascular disease, and cancer was 7.5%, 2.3%, 3.8%, 1.8%, and 1.3%, respectively. Patients with treated hypertension had lower antibody titers than those without hypertension; the multivariable-adjusted ratio of mean (95% CI) was 0.86 (0.76–0.98). Patients with untreated and treated diabetes had lower antibody titers than those without diabetes; the multivariable-adjusted ratio of mean (95% CI) was 0.63 (0.42–0.95) and 0.77 (0.63–0.95), respectively. No substantial difference was observed between the presence or absence of chronic lung disease, cardiovascular disease, or cancer. Patients with untreated hypertension and patients with untreated and treated diabetes had lower spike IgG antibody titers than participants without those medical conditions, suggesting that continuous monitoring of antibody titers and further booster shots could be necessary to maintain adaptive immunity in patients with hypertension or diabetes.
1000 Sacherschließung
lokal Diabetes mellitus
lokal Enzyme-linked immunoassays
lokal Medical conditions
lokal Vaccination and immunization
lokal Antibody therapy
lokal Cancer treatment
lokal Antibodies
lokal Hypertension
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2201-8290|https://orcid.org/0000-0001-5533-3169|https://frl.publisso.de/adhoc/uri/S29qaW1hLCBNYXNheW8=|https://orcid.org/0000-0001-9497-7557|https://frl.publisso.de/adhoc/uri/VG9rdWRhLCBIYXJ1aGlrbw==|https://frl.publisso.de/adhoc/uri/TmlzaGltdXJhLCBLdW5paGlybw==|https://orcid.org/0000-0003-4982-7853|https://frl.publisso.de/adhoc/uri/VGFuYWthLCBTaGlvcmk=|https://orcid.org/0000-0003-1276-2398|https://frl.publisso.de/adhoc/uri/T2htYWdhcmksIE5vcmlv|https://frl.publisso.de/adhoc/uri/WWFtYWd1Y2hpLCBLb3VzaGk=|https://frl.publisso.de/adhoc/uri/VGFrZWRhLCBLYXp1eW9zaGk=|https://orcid.org/0000-0001-6503-8577|https://frl.publisso.de/adhoc/uri/S29uaXNoaSwgTWFraQ==|https://frl.publisso.de/adhoc/uri/TWl5bywgS2VuZ28=|https://frl.publisso.de/adhoc/uri/TWl6b3VlLCBUZXRzdXlh
1000 (Academic) Editor
1000 Label
1000 Förderer
  1. Japan Health Research Promotion Bureau |
1000 Fördernummer
  1. 2020-B-09
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Japan Health Research Promotion Bureau |
    1000 Förderprogramm -
    1000 Fördernummer 2020-B-09
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6452857.rdf
1000 Erstellt am 2023-06-20T08:20:41.796+0200
1000 Erstellt von 337
1000 beschreibt frl:6452857
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Thu Jun 29 14:21:47 CEST 2023
1000 Objekt bearb. Thu Jun 29 14:11:23 CEST 2023
1000 Vgl. frl:6452857
1000 Oai Id
  1. oai:frl.publisso.de:frl:6452857 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source